The efficacy and safety of vidldagliptin combined with acarbose in treating type 2 diabetes
YE Ru-jia
WANG Guang-yao
WANG Xing-hua
SUN Xin-yi
Abstract：Objective To observe the efficacy and safety of vildagliptin combined with acarbose in treating type 2 diabetes. Methods 78 patients with type 2 diabetes were divided into two groups to have additional vildagliptin combined with acarbose or acarbose combined with placebo. The clinical efficacy and adverse reactions after 12 weeks were investigated. Results In the treatment group, FBG, 2 h PG and HbA1C declined after treatment (P < 0.05) and FCP, 2 h CP, FINS and 2 h INS increased (P < 0.05). Compared with the control group, FBG and HbA1c in the treatment group were reduced and owever, FCP, 2 h CP, FINS and 2 h INS were increased more significantly (P < 0.05). There was no difference in the incidence of overall BMI between the two groups (P > 0.05). There were either liver and kidney damage (P > 0.05), nor hypoglycemia. Conclusion Vildagliptin combined with acarbose is superior to Acarbose combined with placebo , and it produced no more untoward effect.
Keywords：Type 2 diabetesVildagliptinAcarboseCurative effect
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 3312-3314 )